Centessa Pharmaceuticals (CNTA) Receives FDA Orphan Designation
GuruFocus
Last updated: June 5, 2026
Centessa Pharmaceuticals received FDA orphan drug designation for cleminorexton, a drug targeting idiopathic hypersomnia. This designation accelerates regulatory processes and offers incentives. However, the company faces financial and valuation concerns, alongside recent insider selling.
- Centessa Pharmaceuticals, a clinical-stage biotechnology company specializing in orexin-based neuroscience, has seen its drug cleminorexton gain orphan drug designation from the FDA for idiopathic hypersomnia. This classification aids in the development of treatments for rare diseases. Despite this regulatory advancement, Centessa's financial standing shows potential challenges, reflected in a GF Score™ of 34/100, particularly a low profitability rank. The company also exhibits reasonable financial strength with a rating of 7/10. Investors should note that Centessa Pharmaceuticals, currently valued at approximately $6.15 billion, operates in the biotechnology sector and is still in its clinical development phase, thus lacking a P/E ratio. Its price-to-sales (P/S) ratio is notably high at 358.83. Furthermore, recent insider activity reveals sales of approximately $12.3 million in shares over the past three months, which could signal concerns regarding the company's future prospects.
